Panacea Pharmaceuticals Inc. presented its paper, "Improved Detection of Cancer Specific Serum Exosomal Aspartyl (Asparaginyl) beta Hydroxylase," and its findings on the company's multi-cancer HAAH exosome detection assay during the annual American Association for Cancer Research meeting in Washington, D.C. April 1-5. Read More »
Pfizer Inc.'s supplemental New Drug Application (sNDA) for Ibrance, its first-in-class cyclin dependent kinase 4/6 (CDK 4/6) inhibitor, has been approved by the U.S. Food and Drug Administration. Read More »
Bracco Imaging has invested in PHS Technologies Group to solidify Bracco's role in the industry and increase the scope of its portfolio software applications related to dose management. Read More »
Daiichi Sankyo Inc. recently announced the enrollment of the first person for its Eliminate-AF study. Read More »
AbbVie's supplemental new drug application for ibrutinib, a product for treating chronic graft vs. host disease (cGVHD) after failure of one or more lines of systemic therapy, has received FDA approval. Read More »
Walgreens and Prime Therapeutics LLC merge to offer specialty pharmacy and mail services Read More »
The U.S. Food and Drug Administration (FDA) has granted Bristol-Myers Squibb Co. a priority review for the company’s Opdivo Biologics License Application. Read More »
Daiichi Sankyo Inc.has sold its pharmaceutical packaging plant in Bethlehem, Pennsylvania to Sharp Packaging Services, a division of UDG Healthcare. Read More »
Biologics Inc., which is owned by McKesson Specialty Health, has been chosen as the exclusive specialty pharmacy provider for BAVENCIO (avelumab). Read More »
Prescription drug costs battles are far from over as PCMA calls for the drug lobby to stop deflecting blame in an effort to maintain profit margins. Read More »
McKesson, the platinum sponsor of CBI’s Formulary, Co-Pay and Access Summit is presenting a new approach to patient-centric behavioral coaching with the overall goal of improving adherence despite affordability and other barriers. Read More »
Pharmacists and the difficult balance they must keep between patients suffering from chronic pain and the prevalence opioid abuse was the topic of a recent special issue of the Journal of the American Pharmacists Association Read More »
Genentech's Ocrevus, the only medicine capable of treating both relapsing and primary progressive forms of multiple sclerosis, has been approved by the U.S. Food and Drug Administration. Read More »
Alcon, a division of Novartis, has received approval from the U.S. Food and Drug Administration for its AcrySof IQ ReSTOR +2.5 Multifocal Toric intraocular lens with ActiveFocus optical design. The product was made for patients with an astigmatism and presbyopia who want to treat them both at the same time with cataract surgery. Read More »
Sanofi and Regeneron Pharmaceuticals recently presented Phase 3 Chronos study results at the late-breaking oral abstract session of the Annual Meeting of the American Academy of Dermatology. Read More »
Praising President Donald Trump’s recent executive order to redirect the previous administration’s energy regulations, a spokesman for the grassroots Americans for Prosperity (AFP) has issued a statement of support. Read More »
The voluntary recall of select lots of EpiPen Auto-Injectors and EpiPen Jr devices has been expanded. Read More »
The Truth Initiative and CVS Health Foundation have launched an initiative to combat tobacco use at historically black colleges and universities (HBCUs). Read More »
Sanofi and Regeneron Pharmaceuticals Inc.'s Dupixent injection has been approved by the U.S. Food and Drug Administration (FDA) for use treating adults with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies. Read More »
Shire plc recently delivered data at the American Academy of Allergy, Asthma & Immunology annual meeting on its Cuvitru drug, which treats patients with primary immunodeficiency. Read More »
Alerts Sign-up
